WO2016143745A1 - Produit à base de thé fermenté - Google Patents

Produit à base de thé fermenté Download PDF

Info

Publication number
WO2016143745A1
WO2016143745A1 PCT/JP2016/057009 JP2016057009W WO2016143745A1 WO 2016143745 A1 WO2016143745 A1 WO 2016143745A1 JP 2016057009 W JP2016057009 W JP 2016057009W WO 2016143745 A1 WO2016143745 A1 WO 2016143745A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
trihydroxyphenyl
propan
fermented
promoting
Prior art date
Application number
PCT/JP2016/057009
Other languages
English (en)
Japanese (ja)
Inventor
栄治 福島
祐子 吉本
Original Assignee
サントリーホールディングス株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サントリーホールディングス株式会社 filed Critical サントリーホールディングス株式会社
Priority to AU2016230139A priority Critical patent/AU2016230139B2/en
Priority to NZ734801A priority patent/NZ734801A/en
Priority to JP2017505328A priority patent/JP6412248B2/ja
Priority to MYPI2017703267A priority patent/MY184881A/en
Publication of WO2016143745A1 publication Critical patent/WO2016143745A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/065—Diphenyl-substituted acyclic alcohols

Definitions

  • the present invention relates to a tea fermentation product. More specifically, the present invention relates to various compositions containing a catechin metabolite that is a tea fermentation product, a method for producing the composition, a method for producing a food and drink using the composition obtained by the production method, and the food and drink.
  • Non-Patent Documents 1 and 2 reports that Awabancha has a higher energy metabolism promoting effect than green tea. When energy metabolism is promoted, it is thought that the body temperature rises and eventually leads to various health such as improvement of cold symptoms, anti-obesity, and increased metabolism, but little is known about its active ingredients in microbial fermented tea.
  • Non-Patent Document 3 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-in which epigallocatechin is reductively opened in microbial fermented tea It is reported that trihydroxyphenyl) -propan-2-ol is contained. So far 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 ⁇ , 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol has been produced by certain intestinal bacteria Although it is known (Non-Patent Document 4), there is no report on its physiological activity.
  • An object of the present invention is to contain 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2 ⁇ , 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol as an active ingredient
  • the object is to provide a composition for enhancing energy metabolism, a composition for enhancing sympathetic nerve activity, a composition for promoting fat burning, a composition for anti-obesity, and a composition for increasing body temperature.
  • the subject of this invention is providing the food-drinks using the composition obtained by this manufacturing method, the manufacturing method of the composition containing the said active ingredient, and its manufacturing method.
  • the present invention relates to the following [1] to [8].
  • [1] 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol for enhancing energy metabolism Composition.
  • [2] Increased sympathetic nerve activity containing 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol Composition.
  • [3] Promotion of fat burning comprising 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol Composition.
  • Anti-obesity composition comprising 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol object.
  • Composition for raising body temperature comprising 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol object.
  • the composition for promoting energy metabolism of the present invention has an excellent effect of being excellent in the action of enhancing energy metabolism.
  • the composition for enhancing sympathetic nerve activity of the present invention has an excellent effect of being excellent in enhancing the sympathetic nerve activity.
  • the composition for promoting fat burning according to the present invention has an excellent effect of being excellent in promoting fat burning.
  • the anti-obesity composition of the present invention has an excellent effect of being excellent in anti-obesity action.
  • the composition for increasing body temperature of the present invention has an excellent effect of being excellent in increasing body temperature.
  • composition obtained by the production method of the present invention is 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2 -ol is contained in a high concentration, so it excels in energy metabolism enhancement, sympathetic nerve activity enhancement, fat burning promotion, anti-obesity, excellent body temperature elevation Has an effect.
  • Figure 1 shows the formation of 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol in the fermentation broth of tea extract (A: Fermented catechin purified product, B: Tea extract before fermentation, C: Tea extract after fermentation (after culturing for 72 hours using TUA4337L)).
  • Figure 2 shows the time course of 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol in the tea extract fermentation broth It is a figure which shows a typical production amount.
  • FIG. 3 shows the production results of 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol by various lactic acid bacteria.
  • FIG. Figure 4 shows the results of enhancement of sympathetic nerve activity by 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol
  • FIG. 5 shows the fourth day after administration of 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2 ′′, 4 ′′, 6 ′′ -trihydroxyphenyl) -propan-2-ol.
  • FIG. 6 shows changes in respiratory quotient by 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol (*: P ⁇ 0.05 t-test).
  • FIG. 7 is a graph showing the results of body temperature increase by 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2 ′′, 4 ′′, 6 ′′ -trihydroxyphenyl) -propan-2-ol (*: P ⁇ 0.05 t-test).
  • FIG. 6 shows changes in respiratory quotient by 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol (*: P ⁇ 0.05 t-test).
  • FIG. 7 is a graph showing the results of body temperature increase by 1- (3 ′, 4 ′, 5′-trihydroxy
  • composition for enhancing energy metabolism, the composition for enhancing sympathetic nerve activity, the composition for promoting fat burning, the composition for anti-obesity, or the composition for increasing body temperature of the present invention is 1- (3 ′, 4 ′, 5 ′ -trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol as an active ingredient. That is, the composition of the present invention contains 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2 ⁇ , 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol, respectively.
  • “energy metabolism” means the process of converting energy released when ATP is converted to ADP into muscle contraction, neurotransmission, substance composition, thermoregulation, etc., and oxygen consumption and Calculated as energy consumption from carbon dioxide emissions.
  • “Sympathetic nerve” means a sympathetic nerve in brown adipose tissue, which is a heat-producing tissue. When sympathetic nerve activity is increased, energy metabolism is increased, leading to increased body temperature, fat burning, and anti-obesity.
  • “Fat burning” is based on the respiratory quotient, which is the volume ratio of the carbon dioxide emission to the oxygen consumption, and means that fat is burned as the respiratory quotient decreases. “Anti-obesity” means that weight gain is suppressed or weight is decreased.
  • 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 ⁇ , 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol should be prepared according to known organic chemical synthesis methods For example, it can be prepared by hydrogenation using a platinum group catalyst using epigallocatechin as a material.
  • 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 ⁇ , 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol is also produced from epigallocatechin by biological transformation It is known (Non-Patent Document 4). In the present invention, for example, it can be obtained by culturing bacteria belonging to Lactobacillus pentosas using a tea extract.
  • the microorganism belonging to Lactobacillus pentosus is not particularly limited as long as it is a known one.
  • the identification sign NRIC 0883 and the accession number NITE BP-1479 are dated on December 10, 2012 as an independent administration.
  • the Lactobacillus pentosaus TUA4337L strain deposited at the Japan Institute for Product Evaluation Technology Patent Microorganism Depositary Center (2-5-8 Kazusa Kamashichi, Kisarazu City, Chiba Prefecture, Japan) can be suitably used.
  • Lactobacillus pentosus TUA4337L strain is abbreviated as TUA4337L strain.
  • each of the compositions containing 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol It can be provided as an active ingredient of the composition for enhancing energy metabolism, the composition for enhancing sympathetic activity, the composition for promoting fat burning, the composition for anti-obesity, or the composition for raising body temperature of the present invention.
  • the administration form of the composition for enhancing energy metabolism, the composition for enhancing sympathetic nerve activity, the composition for promoting fat burning, the composition for anti-obesity, or the composition for raising body temperature of the present invention is not limited.
  • the term “administration” is used to include all modes of administration, ingestion, taking, and drinking.
  • compositions for enhancing energy metabolism are manifested by their administration.
  • administration There is no particular limitation as long as it is effective.
  • body temperature rise, cooling improvement, anti-obesity, visceral fat reduction, beauty, promotion of metabolism, immune activation, anti-fatigue, antidepressant and the like are exemplified.
  • the composition for enhancing energy metabolism, the composition for enhancing sympathetic activity, the composition for promoting fat burning, the composition for anti-obesity, or the composition for increasing body temperature of the present invention is, for example, 1- (3 ′, 4 ′, 5'-trihydroxyphenyl) -3- (2 ⁇ , 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol, if desired, solvent, dispersant, emulsifier, buffer, stabilizer, excipient, Add binders, disintegrants, lubricants, etc., and in accordance with known methods, into solids such as tablets, granules, powders, powders, capsules, etc., or liquids such as normal solutions, suspensions, emulsions, etc. It can also be formulated.
  • the content of 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2 ⁇ , 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol in the above form is Considering the administration form, administration method, etc., the amount is not particularly limited as long as the desired effect of the present invention can be obtained.
  • the content ratio (content) of 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 ⁇ , 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol is usually 0.0001 ⁇ It is about 100% by weight, preferably 0.001 to 30% by weight, more preferably about 0.01 to 5% by weight.
  • the content of 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 ⁇ , 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol was measured according to a known method For example, it can be measured by subjecting it to HPLC.
  • composition for enhancing energy metabolism, the composition for enhancing sympathetic nerve activity, the composition for promoting fat burning, the composition for anti-obesity, or the composition for raising body temperature of the present invention can be administered by an appropriate administration method depending on the form.
  • Be administered can be administered by internal use, external use or injection.
  • it can be taken orally, for injection it can be administered, for example, intravenously, intramuscularly, subcutaneously, intradermally, for external use, for example, external preparations such as suppositories As such, it may be administered by its suitable administration method.
  • the dosage of the composition for enhancing energy metabolism, the composition for enhancing sympathetic nerve activity, the composition for promoting fat burning, the composition for anti-obesity, or the composition for increasing body temperature of the present invention is their form, administration method, use It is appropriately set according to the purpose and the age, weight, and symptoms of a human or animal subject to whom the composition is administered, and is not constant.
  • the effective human intake of 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2 ⁇ , 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol in the present invention It is preferably about 1 mg to 10 g, more preferably about 10 mg to 3 g, and still more preferably about 100 mg to 1 g per day for a human weighing 50 kg. Further, the administration may be performed once or divided into several times within one day within a desired dose range. The administration period is also arbitrary.
  • the subject of administration of the composition for enhancing energy metabolism, the composition for enhancing sympathetic nerve activity, the composition for promoting fat burning, the composition for anti-obesity, or the composition for increasing body temperature of the present invention is preferably It is a human who requires treatment or prevention of increased energy metabolism, increased sympathetic nerve activity, fat burning, weight gain suppression or weight loss, or increased body temperature, such as cows, horses, goats, etc. It may be a domestic animal, a pet animal such as a dog, a cat or a rabbit, or a laboratory animal such as a mouse, rat, guinea pig or monkey.
  • the present invention also provides 1- (3 ′, 4 ′, 5) to individuals who need increased energy metabolism, increased sympathetic activity, promoted fat burning, reduced weight gain or reduced body weight, or increased body temperature.
  • a method for promoting combustion a method for suppressing weight gain or a method for reducing weight, or a method for increasing body temperature.
  • an individual who needs an increase in energy metabolism, an increase in sympathetic nerve activity, an acceleration of fat burning, a suppression of weight gain or a decrease in body weight, or an increase in body temperature refers to the composition for enhancing energy metabolism of the present invention, the sympathy This is the same as the administration subject of the composition for enhancing nerve activity, the composition for promoting fat burning, the composition for anti-obesity, and the composition for raising body temperature.
  • the therapeutically effective amount is 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2 ⁇ , 4 '', 6 ''-trihydroxyphenyl) -propan-2-
  • the amount of increased energy metabolism, the amount of enhanced sympathetic nerve activity, the amount of promoting fat burning, the suppression of weight gain or the reduction of body weight compared to individuals not administered The amount, or the amount by which body temperature rises.
  • the specific effective amount is appropriately set according to the administration form, administration method, purpose of use, individual age, weight, symptoms, etc., and is not constant.
  • 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2 ′′, 4 ′′, 6 ′′ -trihydroxyphenyl) -propan is used so that the therapeutically effective amount is obtained.
  • the composition can be administered. Moreover, there is no limitation also in the administration method, For example, it can administer by oral administration.
  • composition of this invention the composition obtained by the manufacturing method characterized by including the process of fermenting a tea extract with the microbe which belongs to a Lactobacillus pentosus, for example is mentioned as a suitable example.
  • said manufacturing method may be described as the manufacturing method of this invention.
  • the tea leaves contain various catechins, and so-called microbial fermented tea leaves (post-fermented tea leaves) naturally fermented in fermentation barrels such as Awaban tea and Soseki tea also contain compounds represented by the above formula (I). It is known that However, the microbial species that produce the compound represented by the formula (I) is not known and is not fermented using a specific microbial species. In particular, the compound represented by the formula (I) is produced together with other compounds.
  • the compound represented by the formula (I) may not be extracted well or may be decomposed.
  • the present inventors have surprisingly obtained a composition containing a high content of the compound represented by the formula (I) by bringing a fungus belonging to Lactobacillus pentosas into contact with an extract from tea leaves. For the first time, it has been found that the composition has an action of enhancing energy metabolism.
  • 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2 ′) is obtained from epigallocatechin by fermenting the tea extract with a bacterium belonging to Lactobacillus pentosas. This is based on what the present inventors have found that metabolism to ', 4' ', 6' '-trihydroxyphenyl) -propan-2-ol is promoted.
  • the fermented liquid can be used as is, and 1- (3 ', 4', 5'-trihydroxyphenyl) -3- ( 2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol can be easily ingested.
  • tea extract used in the present invention for example, one obtained by extracting tea leaves with a known solvent can be used. Moreover, in this invention, you may use the extract containing many epigallocatechin which is the precursor of the fermentation catechin of this invention from a viewpoint of producing more fermented catechin of this invention.
  • tea leaves include tea leaves such as green tea, black tea, and oolong tea.
  • types of tea leaves include leaves of Camellia family, for example, leaves of Camellia genus tea (Camelliasissinensis).
  • the tea leaf itself or a pulverized product may be used.
  • the solvent examples include any one of hydrophilic organic solvents such as water, ethyl alcohol, and isopropanol, or a combination of these appropriately.
  • the extraction conditions are not generally set according to the apparatus used or the amount used, but for example, the extraction temperature is 30 to 100 ° C., preferably 40 to 80 ° C.
  • the extraction temperature is 30 to 100 ° C., preferably 40 to 80 ° C.
  • a commercial product may be used as the tea extract.
  • bacteria belonging to Lactobacillus pentosas used here those described above can be similarly used.
  • lactic acid bacteria-containing substances such as the lactic acid bacteria culture solution.
  • Dead bacteria can be obtained, for example, by subjecting live bacteria to heating, ultraviolet irradiation, formalin treatment, acid treatment, and the like.
  • the obtained live bacteria and dead bacteria can be further processed by grinding or crushing.
  • the lactic acid bacteria in each said form act on epigallocatechin and produce the fermentation catechin of this invention, although it is preferable that it is a living microbe, a dead microbe may be mixed.
  • the fermentation conditions by the bacteria are not particularly limited as long as they are fermented in a tea extract.
  • an additive containing a carbon source, a nitrogen source, inorganic salts, organic nutrients, and the like is added for fermentation. You may let them.
  • yeast extract which is an extract obtained by extracting components in yeast by treatment with enzyme, hot water, or the like, can be added to the tea extract as a nitrogen source. Fermentation temperature becomes like this.
  • it is 10 degreeC or more, More preferably, it is 15 degreeC or more, More preferably, it is 28 degreeC or more,
  • it is 45 degrees C or less, More preferably, it is 40 degrees C or less, More preferably, it is 38 degrees C or less.
  • the pH of the tea extract is preferably pH 3.0 to 12.5, more preferably pH 3.5 to 10.0, and still more preferably pH 4.0 to 7.0.
  • the fermentation time is not generally determined according to the fermentation temperature or the sample amount, but is, for example, 16 to 96 hours.
  • a composition containing trihydroxyphenyl) -propan-2-ol can be obtained.
  • the content of the fermented catechin of the present invention in the obtained fermented catechin-containing composition cannot be set unconditionally depending on the type of tea extract or fungus, fermentation conditions, subsequent processing conditions described below, etc., but preferably 0.13 mg / mL or more, more preferably 0.5 mg / mL or more, still more preferably 1.0 mg / mL or more.
  • metabolism from epigallocatechin to the fermented catechin of the present invention is promoted by the bacteria belonging to Lactobacillus pentosas, and therefore the weight content of epigallocatechin and fermented catechin in the fermented catechin-containing composition of the present invention
  • the ratio (epigallocatechin / fermented catechin) is preferably 50/50 or less, more preferably 40/60 or less, still more preferably 30/70 or less, still more preferably 20/80 or less, and even more preferably 10/90 or less.
  • Metabolism may be promoted to such an extent that epigallocatechin is not substantially contained.
  • “substantially not contained” means, for example, that the content is 0.01 mg / mL or less as long as it is below the detection limit in the measurement method shown in the Examples below. .
  • the content of epigallocatechin-3-O-gallate in the fermented catechin-containing composition of the present invention is preferably 0.16 mg / mL or more, more preferably 0.5 mg / mL or more, and further preferably 1.0 mg / mL or more.
  • the weight ratio of fermented catechin to epigallocatechin-3-O-gallate is preferably 20/80 or more, more preferably 40/60 or more, more preferably 45/55 or more.
  • the fermented catechin-containing composition of the present invention contains caffeine, gallic acid, epicatechin, epicatechin-3-O-gallate, catechin, gallocatechin, gallocatechin-3-O-gallate, pyrogallol, etc. in addition to the fermented catechin and the compounds described above May be.
  • Their content is not particularly limited as long as it does not impair the effects of the present invention.
  • the compound represented by the formula (I), epigallocatechin-3-O-gallate, epigallocatechin, and other compounds can be measured according to the measurement methods described in the examples below.
  • the obtained fermented catechin-containing composition of the present invention one or more selected from the group consisting of filtration, centrifugation, concentration, ultrafiltration, lyophilization, powdering, and fractionation
  • the treatment may be performed according to a known method, or may be formulated as it is, or may be prepared in a form that can be used for raw materials such as foods and drinks (health foods). Therefore, the said processed material is contained as one aspect
  • the composition for enhancing energy metabolism, the composition for enhancing sympathetic nerve activity, the composition for promoting fat burning, the composition for anti-obesity, or the composition for increasing body temperature of the present invention is used as a food or drink. And as another aspect, it is food-drinks which use the fermented catechin containing composition of this invention obtained by the manufacturing method of this invention as a raw material.
  • the production method thereof is not particularly limited, and the amount of addition, addition time, and method of addition of the fermented catechin-containing composition are not limited.
  • carriers, bases, and / or additives that are usually used in the pharmaceutical field, food field, and the like can be appropriately blended within a range that achieves the object of the present invention.
  • a known food or drink may originally contain the compound represented by the formula (I).
  • the content of 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol is Usually, it is about 0.00002 to 100% by weight, preferably about 0.0002 to 30% by weight, more preferably about 0.002 to 5% by weight.
  • the composition for enhancing energy metabolism the composition for enhancing sympathetic activity, the composition for promoting fat burning, the composition for anti-obesity, or the composition for increasing body temperature of the present invention, and the production method of the present invention.
  • the form of the obtained food or drink is not particularly limited.
  • carbonated drink natural fruit juice, fruit juice drink, soft drink (including fruit juice), fruit drink, fruit food with fruit granules, vegetable drink, soy milk / soy milk Beverages, coffee beverages, tea beverages, jelly beverages, powdered beverages, concentrated beverages, sports beverages, nutritional beverages, alcoholic beverages and other favorite beverages, nutritional foods, supplements, pills, hard capsules, soft capsules, tablets (plain tablets, Sugar-coated tablets, intraoral quick disintegrating tablets, chewable tablets (chewable tablets), effervescent tablets, troches, film-coated tablets, etc.).
  • these should just add the fermented catechin containing composition of this invention to the existing food-drinks at the time of preparation or after preparation, and it does not specifically limit about an addition time and the addition method.
  • the food or drink obtained by the production method of the present invention is the composition for enhancing energy metabolism, the composition for enhancing sympathetic nerve activity, the composition for promoting fat burning, the composition for anti-obesity, or the composition for increasing body temperature of the present invention.
  • it contains a compound represented by the formula (I). Therefore, the food and drink obtained by the production method of the present invention enhances sympathetic nerve activity, such as an energy metabolism enhancing action, a fat burning promoting action, a weight gain inhibiting or weight reducing action, a body temperature raising action, etc.
  • foods and beverages obtained by the production method of the present invention include a composition for enhancing energy metabolism, a composition for enhancing sympathetic nerve activity, and a composition for promoting fat burning.
  • this invention also provides the food / beverage products containing the fermented catechin containing composition of this invention as food / beverage products obtained by the manufacturing method of the food / beverage products of this invention.
  • energy metabolism means the process of converting energy released when ATP is converted to ADP into muscle contraction, nerve transmission, substance composition, body temperature regulation, etc., and oxygen consumption. It is calculated as energy consumption from the amount and carbon dioxide emission.
  • Spor nerve means a sympathetic nerve in brown adipose tissue, which is a heat-producing tissue. When sympathetic nerve activity is increased, energy metabolism is increased, leading to increased body temperature, fat burning, and anti-obesity.
  • “Fat burning” is based on the respiratory quotient, which is the volume ratio of the carbon dioxide emission to the oxygen consumption, and means that fat is burned as the respiratory quotient decreases. “Anti-obesity” means that weight gain is suppressed or weight is decreased.
  • the food or drink obtained by the production method of the present invention is the composition for enhancing energy metabolism, the composition for enhancing sympathetic nerve activity, the composition for promoting fat burning, the composition for anti-obesity, or the composition for increasing body temperature of the present invention.
  • it is suitably used for symptoms that require an action of enhancing energy metabolism, an action of raising body temperature, an action of burning fat, and an anti-obesity action.
  • it is suitably used for body temperature increase, cooling improvement, anti-obesity, visceral fat reduction, beauty, promotion of metabolism, immune activation, anti-fatigue, antidepressant and the like.
  • the composition for enhancing energy metabolism the composition for enhancing sympathetic nerve activity, the composition for promoting fat burning, the composition for anti-obesity, or the composition for increasing body temperature of the present invention, and the production of the present invention
  • the food and drink obtained by the method has an action of enhancing sympathetic nerve activity, which is extremely effective in improving and preventing symptoms that require an action of enhancing energy metabolism, an action of raising body temperature, an action of burning fat, and an anti-obesity action. Useful.
  • the composition for enhancing energy metabolism is used as a health functional food or health food with the purpose of preventing or improving the above symptoms, or 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 ⁇ , 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol is a food with a functional label regarding the functions of, for example, not only individuals who need increased energy metabolism but also energy metabolism.
  • the composition for enhancing energy metabolism the composition for enhancing sympathetic activity, the composition for promoting fat burning, the composition for anti-obesity, or the composition for increasing body temperature of the present invention, and the production method of the present invention.
  • the obtained food or drink can display its use.
  • the content of the indication include, for example, lactic acid bacteria fermented product or 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol
  • the said display may be attached
  • the composition for enhancing energy metabolism the composition for enhancing sympathetic activity, the composition for promoting fat burning, the composition for anti-obesity, or the composition for increasing body temperature of the present invention, and the production method of the present invention.
  • the intake of the obtained food or drink is not set and is appropriately determined depending on the form, intake method, purpose of intake, and the age, weight, and symptom of the person who is the intake of the food or drink.
  • Example 1 Fermented tea extract using TUA4337L strain to give 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol Generated. Specifically, it is as follows. In addition, 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2 ′′, 4 ′′, 6 ′′ -trihydroxyphenyl) -propan-2-ol is referred to as fermentation catechin.
  • ⁇ Fermentation procedure> (1) 1% v / v inoculation of TUA4337L from glycerol stock to MRS (10mL) (2) Culture (30 °C, 20hr) (3) After centrifugation (8,000rpm, 5min, 4 °C), remove supernatant (4) Wash with sterilized water in the same volume as the culture solution ( ⁇ 2) (5) Prepare bacterial solution using sterilized water so that OD 660 10.
  • the obtained culture broth was diluted with pure water, further diluted 2-fold with 40% acetonitrile, treated with a 0.45 ⁇ m filter, and subjected to the following analysis.
  • a typical HPLC chart is shown in FIG. 1, and the production results of fermented catechins are shown in FIG.
  • Example 2 The production of fermented catechins by various strains belonging to lactic acid bacteria was examined.
  • Example 3 The effect of fermented catechin obtained in Example 1 on sympathetic nerve activity in brown adipose tissue was examined.
  • the fermented catechin obtained in Example 1 is a product obtained by isolating and concentrating the peak fraction of fermented catechin from the culture solution in Example 1 and then precipitating it by lyophilization.
  • a cannula for duodenal administration was inserted, and then the sympathetic nerve branch of the interscapular brown adipose tissue was lifted with a silver electrode, and the electrical activity of the nerve was measured.
  • FIG. 4 shows that the fermentation catechin increased significantly in the BAT-SNA value compared to the control.
  • fermented catechins were thought to enhance sympathetic activity in brown adipose tissue.
  • this enhancement of sympathetic nerve activity is a mechanism for enhancing energy metabolism, the following was demonstrated.
  • Example 4 The effect of enhancing energy metabolism and promoting fat burning by the fermented catechin obtained in Example 1 was examined.
  • the fermented catechin used was prepared in the same manner as in Example 3.
  • FIG. 6 shows the difference in respiratory quotient before administration and on the 11th day after administration, but compared to the control group, the respiratory quotient is lower when fermented catechin is administered, and the fat burning effect is promoted. Conceivable.
  • Example 5 The body temperature increasing action by the fermented catechin obtained in Example 1 was examined.
  • the fermented catechin used was prepared in the same manner as in Example 3.
  • C57BL / 6J mice (10 weeks old, male) bred on a high fat diet (60 kcal% FAT) for 2 weeks were tested with 250 ⁇ L of test sample per day (control: sterile water, fermented catechin: 1.6 mg / mL aqueous dispersion) was orally administered (each n 11 to 12).
  • test sample per day control: sterile water, fermented catechin: 1.6 mg / mL aqueous dispersion
  • rectal temperature was measured using a microprobe thermometer (BAT-12, muromachi), and the change width of rectal temperature was calculated. The results are shown in FIG.
  • FIG. 7 shows that fermented catechin significantly increased rectal temperature relative to the control. Therefore, it is considered that fermented catechin has an effect of increasing body temperature.
  • Example 6 The anti-obesity action by the fermented catechin obtained in Example 1 was examined.
  • the fermented catechin used was prepared in the same manner as in Example 3.
  • FIG. 8 shows that the administration of fermented catechin tends to suppress weight gain, and fermented catechin is considered to have an anti-obesity effect.
  • the action of promoting energy metabolism is considered as well as the effect of increasing body temperature.
  • compositions of the present invention will be exemplified. These compositions can be prepared according to known methods.
  • Formulation example Green tea beverage 1
  • the culture broth of Example 1 was dried and then mixed with 9 times the amount of dextrin to prepare a fermented catechin mixture. After adding the above mixture and powdered tea to water and mixing, sterilized at 121 ° C. for 20 minutes to prepare a green tea beverage To do.
  • Formulation example coffee drink About 10 times weight of boiling water is added to 200 g of coffee beans (L value: 27), and Bx. Obtain 2000 g of 2.6 coffee extract.
  • a coffee beverage is prepared by mixing this extract with the mixture prepared at the time of the green tea beverage, granulated sugar, milk, and a pH adjuster.
  • Formulation example carbonated beverage After the mixture prepared in the above green tea beverage was dissolved in water, the pH was adjusted to 3.8 using phosphoric acid, and an antioxidant, a fragrance, a sour agent, a sweetener, and a caramel color were added. Appropriate amounts of each are added and stored for about 24 hours. Meanwhile, an appropriate amount of carbon dioxide gas is added, and then a carbonated beverage is obtained through the steps of filtration, bottling and sterilization (heating at 65 ° C. or higher for 10 minutes).
  • Green tea beverage 2 Fermented catechin was isolated from the culture solution of Example 1, dried, then mixed with 9 times the amount of dextrin to prepare a fermented catechin mixture, added to water to the above mixture and powdered tea, mixed and then sterilized at 121 ° C. for 20 minutes To prepare a green tea beverage.
  • [3] Increased sympathetic nerve activity with 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol as an active ingredient Agent.
  • a sympathetic nerve activity enhancer A sympathetic nerve activity enhancer.
  • Fat burning accelerator containing 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol as an active ingredient .
  • An anti-obesity agent containing 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2 ′′, 4 ′′, 6 ′′ -trihydroxyphenyl) -propan-2-ol as an active ingredient.
  • a body temperature increasing agent containing 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2 ′′, 4 ′′, 6 ′′ -trihydroxyphenyl) -propan-2-ol as an active ingredient.
  • a composition containing 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2 ′′, 4 ′′, 6 ′′ -trihydroxyphenyl) -propan-2-ol as an active ingredient To raise body temperature.
  • the composition for enhancing energy metabolism, the composition for enhancing sympathetic nerve activity, the composition for promoting fat burning, the composition for anti-obesity, and the composition for increasing body temperature have an excellent energy metabolism enhancing action and sympathetic nerve activity. It has an enhancing action, a fat burning promoting action, an anti-obesity (inhibition of weight gain or weight reduction) action, a body temperature raising action, for example, body temperature rise, cooling improvement, anti-obesity, visceral fat reduction, beauty, Expected to be effective in promoting metabolism, immune activation, anti-fatigue, antidepressant, etc.
  • composition containing 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2 ⁇ , 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol obtained by the production method of the present invention
  • the substance has excellent energy metabolism enhancing action, sympathetic nerve activity enhancing action, fat burning promoting action, body weight gain inhibiting or body weight reducing action, body temperature raising action, for example, body temperature rise, coldness Improvement, anti-obesity, visceral fat reduction, beauty, promotion of metabolism, immune activation, anti-fatigue, antidepressant, etc. can be expected.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Tea And Coffee (AREA)
  • Non-Alcoholic Beverages (AREA)

Abstract

L'invention concerne une composition destinée à stimuler le métabolisme énergétique, une composition destinée à stimuler l'activité du nerf sympathique, une composition destinée à stimuler la combustion des graisses, une composition anti-obésité ou une composition destinée à accroître la température corporelle, chaque composition comprenant du 1-(3',4',5'-trihydroxyphényl)-3-(2",4",6"-trihydroxyphényl)-propan-2-ol. Les compositions selon la présente invention possèdent d'excellents effets de stimulation du métabolisme énergétique, de stimulation de l'activité du nerf sympathique, de stimulation de la combustion des graisses, de lutte contre l'obésité (c.-à-d. suppression du gain de poids corporel ou réduction du poids corporel) et d'augmentation de la température corporelle. Par conséquent, ces compositions peuvent éventuellement être efficaces pour accroître la température corporelle, améliorer l'hypothermie, lutter contre l'obésité, réduire la graisse viscérale afin de produire des effets cosmétiques, de stimuler le métabolisme, de stimuler l'immunité, de soulager la fatigue, d'améliorer la dépression, etc.
PCT/JP2016/057009 2015-03-09 2016-03-07 Produit à base de thé fermenté WO2016143745A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2016230139A AU2016230139B2 (en) 2015-03-09 2016-03-07 Fermented tea product
NZ734801A NZ734801A (en) 2015-03-09 2016-03-07 Fermented tea product
JP2017505328A JP6412248B2 (ja) 2015-03-09 2016-03-07 茶発酵物
MYPI2017703267A MY184881A (en) 2015-03-09 2016-03-07 Fermented tea product

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2015-046416 2015-03-09
JP2015046415 2015-03-09
JP2015046416 2015-03-09
JP2015-046415 2015-03-09

Publications (1)

Publication Number Publication Date
WO2016143745A1 true WO2016143745A1 (fr) 2016-09-15

Family

ID=56880159

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2016/057009 WO2016143745A1 (fr) 2015-03-09 2016-03-07 Produit à base de thé fermenté

Country Status (6)

Country Link
JP (2) JP6412248B2 (fr)
AU (1) AU2016230139B2 (fr)
MY (1) MY184881A (fr)
NZ (1) NZ734801A (fr)
TW (1) TWI681719B (fr)
WO (1) WO2016143745A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018046772A (ja) * 2016-09-21 2018-03-29 池田食研株式会社 ４−エチルフェノールの生成方法
JP2018087171A (ja) * 2016-11-29 2018-06-07 株式会社明治 交感神経活性化用組成物
JP2018095569A (ja) * 2016-12-09 2018-06-21 サントリーホールディングス株式会社 基礎代謝亢進剤
JP2021020944A (ja) * 2020-10-26 2021-02-18 サントリーホールディングス株式会社 基礎代謝亢進剤
CN113678918A (zh) * 2020-05-18 2021-11-23 国立大学法人千叶大学 肠道调节用茶发酵组合物及其制造方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011087486A (ja) * 2009-10-21 2011-05-06 Mitsui Norin Co Ltd カテキン代謝物の製造方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011087486A (ja) * 2009-10-21 2011-05-06 Mitsui Norin Co Ltd カテキン代謝物の製造方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JOBU KOHEI ET AL.: "Effects of Goishi tea on diet-induced obesity in mice", FOOD RESEARCH INTERNATIONAL, vol. 54, 2013, pages 324 - 329, XP028750347 *
JUNKO YOKOTA ET AL.: "Effect of Goishi-tea on Adipocytokine Changes", JOURNAL OF THE JAPANESE SOCIETY FOR FOOD SCIENCE AND TECHNOLOGY, vol. 58, no. 8, 2011, pages 398 - 402 *
MISAKO SOGAWA ET AL.: "Awabancha no Motsu Taiju Oyobi Taishibo Gensho Koka", THE JAPANESE SOCIETY OF NUTRITION AND FOOD SCIENCE SOKAI KOEN YOSHISHU, vol. 57 th, 2003, pages 240 *
MISAKO SOGAWA ET AL.: "Shokujisei Himan Rat no Taiju Oyobi Taishibo Gensho ni Oyobosu Awabancha no Koka", THE JAPANESE SOCIETY OF NUTRITION AND FOOD SCIENCE SOKAI KOEN YOSHISHU, vol. 56 th, 2002, pages 160 *
TAKASHI TANAKA ET AL.: "Isolation of 1,3- diphenylpropan-2-ols, identical to tea catechin metabolites produced by intestinal bacteria, and pyrogallol from Japanese post-fermented tea", JAPANESE SOCIETY OF FOOD CHEMISTRY GAKKAISHI, vol. 18, no. 1, 2011, pages 6 - 11, XP055309837 *
YOKOTA JUNKO ET AL.: "The influence of Goishi tea on adipocytokines in obese mice", FOOD CHEMISTRY, vol. 138, 2013, pages 2210 - 2218, XP028996506 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018046772A (ja) * 2016-09-21 2018-03-29 池田食研株式会社 ４−エチルフェノールの生成方法
JP2018087171A (ja) * 2016-11-29 2018-06-07 株式会社明治 交感神経活性化用組成物
WO2018101231A1 (fr) * 2016-11-29 2018-06-07 株式会社明治 Composition permettant l'activation du nerf sympathique
CN110087648A (zh) * 2016-11-29 2019-08-02 株式会社明治 交感神经活化用组合物
US11147791B2 (en) 2016-11-29 2021-10-19 Meiji Co., Ltd. Composition for activating sympathetic nerve
JP2018095569A (ja) * 2016-12-09 2018-06-21 サントリーホールディングス株式会社 基礎代謝亢進剤
CN113678918A (zh) * 2020-05-18 2021-11-23 国立大学法人千叶大学 肠道调节用茶发酵组合物及其制造方法
JP2021020944A (ja) * 2020-10-26 2021-02-18 サントリーホールディングス株式会社 基礎代謝亢進剤

Also Published As

Publication number Publication date
NZ734801A (en) 2019-06-28
JP2019011353A (ja) 2019-01-24
JP6669829B2 (ja) 2020-03-18
AU2016230139A1 (en) 2017-09-21
TWI681719B (zh) 2020-01-11
JP6412248B2 (ja) 2018-10-24
TW201642753A (zh) 2016-12-16
AU2016230139B2 (en) 2018-10-18
JPWO2016143745A1 (ja) 2017-12-28
MY184881A (en) 2021-04-29

Similar Documents

Publication Publication Date Title
JP6669829B2 (ja) 茶発酵物
JP5718917B2 (ja) 新規なラクトバチルス・プランタラム及びこれを含む組成物
KR102156399B1 (ko) 비만의 예방 또는 치료 효과를 가지는 신규 비피도박테리움 롱검 균주 또는 락토바실러스 람노서스 균주 및 이의 용도
JP5888701B2 (ja) 高タンパク質分解活性を有するラクトバチルス・ヘルベティカス菌
JP7041508B2 (ja) 概日リズム改善用組成物
EP4410953A1 (fr) Nouveaux probiotiques et utilisation associée
Liu et al. Functional properties and sensory characteristics of kombucha analogs prepared with alternative materials
WO2015133122A1 (fr) Agent de réglage autonome pour sédation, et agent d'amélioration de rythme quotidien
KR101614929B1 (ko) 인지장애 및 기억장애 치료용 약학 조성물
KR101992331B1 (ko) 피부 미백 및 보습개선 활성을 갖는 류코노스톡 시트리움 WiKim0059 및 이를 포함하는 조성물
JP2007126399A (ja) グルタチオン増加用組成物
KR20130130131A (ko) 흑마늘 발효 식초 조성물 및 그 제조방법
CN113678918A (zh) 肠道调节用茶发酵组合物及其制造方法
KR20100010555A (ko) 관능효과 및 경제성이 뛰어난 기능성 유산균 한방 발효환약의 제조방법
JP6671367B2 (ja) 環状ジペプチド含有抗肥満用組成物
KR101535077B1 (ko) 인슐린 저항성 개선 효능을 가지는 비피도박테리움 락티스 hy8101 및 이를 유효성분으로 함유하는 제품
Ladavac A critical review of purported health benefits of kombucha consumption
KR102578389B1 (ko) 지방간 개선 효능을 갖는 신규 락토바실러스 루테리 균주 및 이의 용도
KR102689442B1 (ko) 프로바이오틱 균주로 발효한 식용 곤충 발효물 및 이의 용도
KR102335928B1 (ko) 비만의 예방, 치료 또는 개선용 조성물
WO2021131568A1 (fr) Composition permettant de supprimer ou d'améliorer la réduction de la quantité d'activité physique
JP2020184909A (ja) 血糖降下剤、及び、該血糖降下剤を含有する飲食品
Park et al. Review of physiological compounds and health benefits of soybean paste (doenjang): exploring its bioactive components
KR20220112951A (ko) 항치매 및 항산화 활성을 가지는 인진쑥 발효물 및 이의 제조방법
WO2020149393A1 (fr) Procédé de sélection de substances améliorant l'odeur des matières fécales, procédé de fabrication de composition améliorant l'odeur des matières fécales, agent améliorant la fonction rénale, et boisson ou aliment destiné à améliorer la fonction rénale

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16761713

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2017505328

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2016230139

Country of ref document: AU

Date of ref document: 20160307

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 16761713

Country of ref document: EP

Kind code of ref document: A1